Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235293 · ClinicalTrials.gov registry record · Phase 2
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
A Phase 2 study of Colorectal Cancer, sponsored by Kahr Bio Australia Pty.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT07235293: Recruiting Phase 2 study of Colorectal Cancer, sponsored by Kahr Bio Australia Pty.
NCT07235293 is a Phase 2 study of Colorectal Cancer that is actively recruiting participants, run by Kahr Bio Australia Pty. The registered enrollment target is 90 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07235293, a Phase 2 study of Colorectal Cancer, is actively recruiting participants, sponsored by Kahr Bio Australia Pty.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Conditions Studied
Interventions
- DRUG Fruquintinib
- DRUG DSP107 + Atezolizumab
Study Locations (16)
Victoria
- Monash Health - Clayton
- Footscray Hospital - Western Health - Footscray
- Austin Health - Heidelberg
- Alfred Health - Melbourne
- Sunshine Hospital - Western Health - Saint Albans
New South Wales
- Chris O'brien Lifehouse - Camperdown
- Westmead Hospital - Westmead
Colorado
- University of Colarodo Cancer Center - Aurora
Florida
- Mayo Clinic - Florida City
North Carolina
- Duke Cancer Institute - Duke Cancer Center - Durham
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Texas City
Adelaide
- The Queen Elizabeth Hospital - Woodville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07235293
The ClinicalTrials.gov registry entry for NCT07235293 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Kahr Bio Australia Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fruquintinib is the first listed.
NCT07235293 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Victoria, New South Wales, Colorado.
Frequently Asked Questions
What is clinical trial NCT07235293 about?
NCT07235293 is a clinical study titled "A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.". This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one ...
What is the current status of trial NCT07235293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-20. Estimated completion is 2027-04-30.
What conditions does trial NCT07235293 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT07235293?
The interventions under investigation include: Fruquintinib (DRUG), DSP107 + Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT07235293?
This trial is sponsored by Kahr Bio Australia Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235293 being conducted?
This trial has 16 study locations across Colorado, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.